Research Study

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Psoriasis
ClinicalTrials.gov# 
NCT04149587
Status 
Recruiting
Study Start/End 
Mar 8, 2021 to Sep 30, 2021
Name/Title 
Sze Wai Ho, Study Coordinator
Phone 
604-875-5296
Email Address 
SzeWai.Ho@ubc.ca
Purpose of Study 

The purpose of this study is to evaluate the effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants with psoriasis who have had an inadequate response to their current biologic agent regimen.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.